Therapeutic effects of intranasally-administered insulin in adults with amnestic mild cognitive impairment (aMCI) or mild Alzheimer’s disease (AD) ADC-046-INI
The purpose of this study is to learn more about Alzheimer’s disease using a called Humulin R which is an intranasally-administered insulin. The purpose of this study is to examine the effects of the study drug on cognition, certain parts of the brain and cerebrospinal fluid in subjects with mild cognitive impairment and Alzheimer’s disease.
Diagnosis of Alzheimer's disease. Age 55-85. Generally good health. Able to make frequent visits to OHSU with caregiver/family member. Admission into this study will be based on memory testing and an MRI scan as well as a physical and neurological exam.
55 - 85
Healthy Volunteers Needed
Duration of Participation
This study requires 11 visits to the clinic and will take 18 months to complete.
Monika Stanko, RN (503)494-7615
National Institute on Aging